Effect of a 3 month depot injection of leuprorelin acetate (Trenantone®) on pre-menopausal breast cancer - Results of a post-marketing surveillance study;Wirkung des 3-monats-depot leuprorelinacetat (Trenantone®) beim prämenopausalen mammakarzinom - Ergebnisse einer anwendungsbeobachtung

Geburtshilfe und Frauenheilkunde

Volumn 68, Issue 10, 2008, Pages 1008-1012

  Grischke, Eva Maria ^a   Fehm, T ^a   Solomayer, E ^a   Hillger, H ^b   Wallwiener, D ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Takeda Pharma GmbH   (Germany)

Author keywords

Efficacy; Hormone sensitive breast cancer; Leuprorelin 3 month depot; Premenopausal women; Therapy; Tolerability

Indexed keywords

ESTRADIOL; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE;

ADJUVANT THERAPY; ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; GYNECOLOGY; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; INJECTION; MAJOR CLINICAL STUDY; POSTMARKETING SURVEILLANCE; PREMENOPAUSE; QUALITY OF LIFE; TIME PERCEPTION; TREATMENT DURATION;

EID: 56149122620     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038944     Document Type: Article

References (13)

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2007; 18: 1133-1144
2. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-1196
3. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942
4. Schmid P, Untch M, Kosse V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE study. J Clin Oncol 2007; 25: 2609-2616
5. Jonat W, Kaufmann M, Sauerbrei W. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. J Clin Oncol 2002; 20: 4628-4635
6. Kaufmann M, Graf E, Jonat W. A randomized trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. Eur J Cancer 2007; 43: 2351-2358
7. Boccardo F, Rubagotti A, Amoroso D. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000; 18: 2718-2727
8. Roche H, Kerbrat P, Bonneterre J. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and receptor-positive, early breast cancer patients: 7 years follow-up results of French Adjuvant Study group 06 randomized trial. Ann Oncol 2006; 17: 1221-1227
9. Jakesz R, Hausmanniger H, Kibista E. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamid, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast-cancer - Austrian breast and colorectal cancer study group Trial 5. J Clin Oncol 2002; 20: 4621-4627
10. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711-1723
11. Tan S-H, Wolff AC. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clinical Breast Cancer 2007; 7: 455-464
12. AGO-Empfehlungen Version 2008.10, www.ago-online.de
13. S3-Leitlinien der DKG Version 1.2008, www.krebsgesellschaft.de